To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

• Status: Recruiting
• Trial end date: 2022-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Prevention of COVID-19 infection to severe pneumonea or ARDS

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Enzychem Lifesciences Corporation

Criteria

Inclusion Criteria:

• Signed informed consent

• Male or female age 19 years or older

• Pathologically confirmed diagnosis of COVID-19 Infection to Pneumonia

Exclusion Criteria:

• Pathologically confirmed diagnosis of bacterial pneumonia or viral pneumonia

• Pregnant or nursing at the time of signing informed consent

• Known sensitivity to any study medication

• Unwilling or unable to complete study diary

• Any other condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the protocol